This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.
specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies. FYI: The material in today’s article is adapted from Section 3.1.
Have you ever found yourself scratching your head at the pharmacy counter, wondering why your “3-month supply” of medication doesn’t quite match up with the calendar? You’re not alone.
In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals. Read on for full details and the latest data.
This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This month, nine biosimilar versions of adalimumab launched in the U.S. No biosimilar has the trifecta of being high-concentration, citrate-free, and fully interchangeable.
In Australia, both methadone and buprenorphine have been subsidised by the Pharmaceutical Benefit Scheme (PBS) for the treatment of opioid dependence (termed ‘opioid agonist treatment’ or OAT) for several decades. Our recent article, published in The International Journal of Drugs , presents the Australia-wide results.
For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. d/b/a Drug Channels Institute.
For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs. Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. drug channels.
As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Last week, the Federal Trade Commission (FTC) released its interim report on pharmacy benefit managers (PBMs). Pharmacies and Pharmacy Benefit Managers.
Cool off by getting up close and personal with our refreshing selection of articles and insights. We are offering our 2019–20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors at discounts up to 35% off. The steamy, socially distanced days of summer are here.
NeedyMeds , a non-profit organization known for providing patients with help in finding pharmaceutical company-sponsored prescription assistance programs and other drug savings options, hosted a webinar about drug importation last year called “ Drug Importation: The topic everyone’s talking about.” Emphasis added).
In this model, once a product is produced and delivered to the clinical pharmacy, the clinical team takes over the trial with little to no interaction with the manufacturing team. Dr. Bock has previously held leadership roles at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences.
FDA addressed the expanding practice of drug compounding in 1992 by issuing a compliance policy guide that clarified that pharmacies which compounded products at certain scales, for certain purposes, or without FDA approval were clearly operating “outside the bounds of traditional pharmacy practice.”
This week, I’m rerunning some popular posts while I work on the forthcoming 2020-21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Since my original article below, MedImpact has released its annual drug trend report. Click here to see the original post and comments from June 2020.
McChesney served as a faculty member at the University of Kansas School of Pharmacy, who presented him with an Outstanding Teaching Award for the 1967 to 1968 academic year. departing in 2003 to become the chief scientific officer for Tapestry Pharmaceuticals and ChromaDex Inc. In 2009, he established Ironstone Separations Inc.,
To help control impurities, the FDA requires all starting materials used in drug manufacturing and final pharmaceutical products to be evaluated for “identity, strength, quality and purity.” Read AgencyIQ’s analysis of the ICH guideline here ].
Many posted comments came from professional pharmacy organizations, trade groups like the Pharmaceutical Research and Manufacturers of America (PhRMA) , and pharmaceutical companies, such a Eli Lilly , Novo Nordisk and Merck.
The potential for Congress to overturn this dynamic could have major and negative effects on the drug’s current owner, Jazz Pharmaceuticals. For example, Epidiolex at present is effectively protected by provisions of DSHEA which limit the introduction of CBD as a legally regulated product due to its status as an approved drug.
Mark Cuban’s new online pharmacy venture – the Mark Cuban Cost Plus Drug Company (“Cost Plus Drug”) – will not help overcome the biggest obstacle to drug affordability in America, which is drug company monopolies on patented brand name prescription drugs. That’s even cheaper than foreign online pharmacy prices , including in India. .
The Commission’s communication was accompanied by a Q&A document defining key terms and ideas, including how the effort was related to ongoing efforts to overhaul the pharmaceuticals legislation. active pharmaceutical ingredient, fill/finish, packaging/labeling). reducing the frequency of a dose) or pharmaceutical form (e.g.,
Drug companies and big chain pharmacies don’t want the competition of lower drug prices offered by international online pharmacies because it means lower profits. They want the FDA to shut down those sites, but, it seems, under current law, the international online pharmacies used to facilitate importation are not illegal.
PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. At some hospitals, it can take up to 30 minutes to get a status epilepticus drug from the pharmacy to the point of care in the ER to treat a patient. About Sedor Pharmaceuticals, LLC. About Sesquient.
Pharmacopeia (USP) and the FDA – to clarify whether the “actual ‘shelf life’ of many pharmaceutical products might be considerably longer than the expiration date that appears on the manufacturer’s container.” And per the FDA, “extension of drug product expiration dating periods is strictly voluntary for pharmaceutical manufacturers.”
doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.
WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025.
Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.
Accelerated Approval of Drugs and Biologics Administrative/ Procedural New Civil Monetary Penalties for Failure to Meet Accelerated Post Marketing Requirements Administrative/ Procedural Carried over from previous guidance agenda Exclusivity for First Interchangeable Biosimilar Biological Products Administrative/ Procedural Carried over from previous (..)
CDRH FY2024 Guidance Agenda Clinical application Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma CBER Final By 12/31/24 CBER CY 2024 Guidance Agenda Blood Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method CBER Draft (..)
Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.
Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.
Recently Recursion Pharmaceuticals unbiased, machine learning-powered genomics screen rapidly identified and advanced REC-1245. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector. This is an AI-generated image.
However, provider pushback has limited specialty pharmacies' share gains, so that buy-and-bill remains the most common channel for these products. Payers adoption of white baggingand providers push backreflect the ongoing battle for oncology margin in U.S. drug channels. Lets hope that patients dont get caught in the crossfire.
This article, along with other insightful analyses, will be featured in our upcoming report, Beyond the Lab – Artificial Intelligence, launching on 21st March 2025. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector.
Cognitant Group partnered with the UK’s National Health Service (NHS) and other global pharmaceutical companies to ensure the content was trustworthy, up-to-date and verified. At launch, the app featured more than 1,100 health ‘A to Z’ articles from the UK’s NHS official website and leading universities.
The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS). Improving drug development success in the face of increasingly complex therapies is therefore a priority for the pharmaceutical industry.
In non-COVID-19 news, Amazon has entered the pharmaceutical market by launching ‘Amazon Pharmacy’ in India, while Johnson & Johnson is set to buy the Cambridge-based Momenta Pharmaceuticals for $6.5 billion, making it the largest pharmaceutical industry deal this year so far. Amazon Pharmacy launches in India.
2023) (First Amendment bars state-law misrepresentation claims over “truth” of published scientific article) ( here ); National Association of Wheat Growers v. 2023) (HHS cannot force pharmaceutical manufacturers to sell unlimited amounts of prescription drugs at a discount) ( here ). Forest Pharmaceuticals, Inc. Bonta , 85 F.4th
The plaintiff “lacks Article III standing because she cannot establish an injury that plausibly corroborates her assertion that the Products she purchased are ‘unreasonably dangerous.’ Wilson applied Nexus Pharmaceuticals, Inc. Central Admixture Pharmacy Services, Inc. , 4th 1040 (9th Cir.
Supporting scientific articles as First Amendment-supported speech, here in 2009. Consequently, unless the plaintiff alleged fraudulent data, scientific articles are protected speech and immune from suit. at *2 (citing, inter alia , Virginia State Board of Pharmacy v. We have tried to be consistent. 2022 WL 336585 (D.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content